Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutations
Timothy R. Rebbeck(Dana-Farber Cancer Institute), Carole Brewer(Royal Devon and Exeter Hospital), Elizabeth J. van Rensburg(University of Pretoria), Lesley Andrews(Prince of Wales Hospital), Dezheng Huo(University of Chicago Medical Center), Amie Blanco(University of California, San Francisco), Goska Leslie(University of Cambridge), Julian Adlard(Chapel Allerton Hospital), Ava Kwong(University of Hong Kong), Jeffrey N. Weitzel(Cancer Genetics (United States)), Eitan Friedman(University of Pennsylvania), Jacopo Azzollini(Fondazione IRCCS Istituto Nazionale dei Tumori), Soo‐Hwang Teo(Cancer Research Malaysia), Marinus J. Blok(Maastricht University), Angela R. Bradbury(University of Pennsylvania), Michael T. Parsons, Daniel Barrowdale(University of Cambridge), Cora M. Aalfs(University of Amsterdam), Aðalgeir Arason(University of Iceland), Javier Benı́tez(Spanish National Cancer Research Centre), Norbert Arnold(Christian-Albrechts-Universität zu Kiel), Raanan Berger(Tel Aviv University), Diana Torres(German Cancer Research Center), Edenir Inêz Palmero(DASA (Brazil)), Ángela R. Solano(Consejo Nacional de Investigaciones Científicas y Técnicas), Rósa B. Barkardóttir(University of Iceland), Ute Hamann(German Cancer Research Center), Ella Asseryanis(Comprehensive Cancer Center Vienna), Julio E. Abugattas(City of Hope), Bernardo Bonanni(European Institute of Oncology), Judith Balmañà(Vall d'Hebron Hospital Universitari), Sue K. Park(Seoul National University), Banu Arun(The University of Texas MD Anderson Cancer Center), Fergus J. Couch, Olufunmilayo I. Olopade(University of Chicago), Valérie Bonadona(Centre Léon Bérard), Monica Barile(European Institute of Oncology), Kristiina Aittomäki(University of Helsinki), Lesley McGuffog(University of Cambridge), Simona Agata(Istituto Oncologico Veneto), Mads Thomassen(Odense University Hospital), Irene L. Andrulis(University of Toronto), Andreas Berger(Comprehensive Cancer Center Vienna), David E. Goldgar(University of Utah), Leo Auerbach(Comprehensive Cancer Center Vienna), Edith Oláh(National Institute of Oncology), Torben A. Kruse(Odense University Hospital), Kathleen R. Blazer(City of Hope), TL Chan(Hong Kong Sanatorium and Hospital), Tara M. Friebel(Fox Chase Cancer Center)
Cited by 319
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k